Filing Details
- Accession Number:
- 0001213900-24-078214
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-12 17:19:07
- Reporting Period:
- 2024-09-12
- Accepted Time:
- 2024-09-12 17:19:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1788028 | Jasper Therapeutics Inc. | JSPR | Biological Products, (No Disgnostic Substances) (2836) | 842984849 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1882877 | Singh Jeetinder Mahal | C/O Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite 102 Redwood City CA 94065 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Voting Common Stock | Acquisiton | 2024-09-12 | 900 | $7.10 | 25,909 | No | 4 | M | Direct | |
Voting Common Stock | Disposition | 2024-09-12 | 900 | $21.23 | 25,009 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Voting Common Stock | Stock Option (right to buy) | Acquisiton | 2024-09-12 | 900 | $0.00 | 900 | $7.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
14,672 | 2030-05-31 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.795 to $21.495, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.